They reported the response duration of this combination therapy for pancreatic cancer was over 18 months and during this period, intravenous IL-2 in compared to subcutaneous administration leads to more platelet decrease, less platelet/lymphocyte decrease, and less Treg cells increase. The gene discussed is IL2; the disease is pancreatic neoplasm.